Johnson & Johnson vs Norfolk Southern Corporation — how do they compare? Johnson & Johnson trades at $249.28 (market cap $598.96B), while Norfolk Southern Corporation trades at $334.41 (market cap $75.23B). The key difference: Johnson & Johnson is far larger — about 8× Norfolk Southern Corporation's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | NSC | |
|---|---|---|
Market Cap | $598.96B | $75.23B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $340.16 |
52-Week Low | $164.36 | $272.35 |
Enterprise Value | $631.90B | $90.99B |
Dividend Yield | 2.15% | 1.61% |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Norfolk Southern (NSC) trades at $334.97, down 1.53% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company shows strong profitability with a 21.91% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights the pending merger with Union Pacific and upcoming Q2 2026 earnings on July 23, 2026.
The stock offers a moderate upside to the $344.40 consensus price target, supported by earnings momentum and cost controls, but faces risks from regulatory scrutiny of the merger and rich valuations. Investor sentiment is mixed amid merger uncertainties and high expectations.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →